Ken Griffin Corvus Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.78 - $5.92 $18,512 - $61,568	10,400 Added 67.53%	25,800 $136,000
Q2 2024 Aug 14, 2024	BUY	$1.36 - $2.29 $11,832 - $19,923	8,700 Added 129.85%	15,400 $28,000
Q1 2024 May 15, 2024	SELL	$1.76 - $2.41 $51,920 - $71,095	-29,500 Reduced 81.49%	6,700 $11,000
Q4 2023 Feb 14, 2024	BUY	$1.08 - $1.92 $20,628 - $36,672	19,100 Added 111.7%	36,200 $63,000
Q3 2023 Nov 14, 2023	SELL	$1.41 - $2.97 $6,345 - $13,365	-4,500 Reduced 20.83%	17,100 $24,000
Q2 2023 Aug 14, 2023	BUY	$1.0 - $3.86 $21,600 - $83,376	21,600 New	21,600 $49,000
Q4 2022 Feb 14, 2023	BUY	$0.74 - $1.04 $814 - $1,144	1,100 New	1,100 $0

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $413M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.